Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anti-Tau
Biotech
AAIC: Roche ‘very interested’ in tau despite amyloid AD focus
Roche’s biggest bet in Alzheimer’s may be its phase 3-stage amyloid asset, but the pharma is keeping its options open when it comes to targeting tau.
James Waldron
Jul 15, 2026 8:42am
Lilly pays AC Immune $12.5M to expand Alzheimer’s collab
Apr 7, 2026 9:30am
J&J halts enrollment in trial of AC Immune Alzheimer's drug
Feb 19, 2026 9:50am
J&J's anti-tau antibody posdinemab flops in phase 2
Nov 24, 2025 9:40am
UCB's tau drug flunks Alzheimer's trial days after Roche's exit
Nov 1, 2024 6:01am
Roche tosses out $120M tau prospect, returning rights to UCB
Oct 22, 2024 8:30am
